PAH and phenylketonuria: Beyond sapropterin, a phenylalanine hydroxylase endogenous ligand used since 2007 in the treatment of phenylketonuria (see Section 3.1), the anti-aggregative protein binder tafamadis was approved in 2012 against the neurodegenerative disease transthyretin-related hereditary amyloidosis [19].